Evaluating the role of botulinum toxin in the management of focal hypertonia in adults

OBJECTIVES To investigate the effects of EMG guided botulinum toxin (BTX-A) on impairment and focal disability in adults presenting with focal hypertonia. METHODS A prospective, randomised, double blind, placebo controlled, parallel group trial was carried out with standardised assessment before and at 3 week intervals until 12 weeks after injection, in patients with focal hypertonia affecting upper or lower limbs. Botulinum toxin or placebo was injected with EMG guidance after multidisciplinary assessment. The modified Ashworth scale of spasticity, percentage passive range of joint motion, subjective rating of problem severity, the Rivermead motor assessment scale, a timed 10 metre walk (lower limb patients), nine hole peg test (upper limb patients), and a modified goal attainment scale were used as outcome measures. The patients were 52 adults; 34 male, 18 female; mean age 40.31, range 16–79 years; mean duration of symptoms 35 months (range 3 months to 22 years). Diagnoses included cerebrovascular accidents (23), head injury (12), incomplete spinal cord injury (six), tumour (five), cerebral palsy (three), and anoxic episodes (three). RESULTS For each variable an overall score for the treatment period was computed by summing the scores from the 3, 6, 9, and 12 week assessments. These overall scores were significantly better in the treated group for the Ashworth scale, percentage passive range of movement, Rivermead lower limb, and subjective rating of problem severity. The significant treatment effect on the Ashworth scale was seen on analysis of variance (ANOVA) at 3 weeks and the subjective rating of problem severity at 3 and 6 weeks. The goal attainment scale score in both groups was similar at 12 weeks. CONCLUSION Selective use of botulinum toxin to weaken muscles can lead to a reduction in resistance to passive movement about a distal limb joint. This allows for improvements in passive range of movement and focal disability, particularly in patients presenting with focal spasticity of the lower limb.

[1]  G. Yarkony,et al.  Contractures A Major Complication of Craniocerebral Trauma , 1987, Clinical orthopaedics and related research.

[2]  K. Mauritz,et al.  Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. , 1996, Stroke.

[3]  M. Brin,et al.  Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult‐onset spasticity , 1997, Muscle & nerve. Supplement.

[4]  V. Mathiowetz,et al.  Reliability and validity of grip and pinch strength evaluations. , 1984, The Journal of hand surgery.

[5]  J Quintern,et al.  Electrophysiological studies of gait in spasticity and rigidity. Evidence that altered mechanical properties of muscle contribute to hypertonia. , 1981, Brain : a journal of neurology.

[6]  P. Neilson,et al.  Spasticity and muscle contracture following stroke. , 1996, Brain : a journal of neurology.

[7]  M. Muhlenhaupt.  Measurement of Joint Motion: A Guide to Goniometry , 1986 .

[8]  D. Wade,et al.  Walking after stroke. Measurement and recovery over the first 3 months. , 2020, Scandinavian journal of rehabilitation medicine.

[9]  J. Black,et al.  Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization , 1984, Nature.

[10]  P. Brown.  Pathophysiology of spasticity. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[11]  S. Hesse,et al.  Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial , 1998, Clinical rehabilitation.

[12]  H. Graham,et al.  Botulinum toxin A in the management of children with cerebral palsy: indications and outcome , 1997 .

[13]  A P Cosgrove,et al.  BOTULINUM TOXIN IN THE MANAGEMENT OF THE LOWER LIMB IN CEREBRAL PALSY , 1994, Developmental medicine and child neurology.

[14]  T K Das,et al.  Effect of treatment with botulinum toxin on spasticity. , 1989, Postgraduate medical journal.

[15]  Richard W. Bohannon,et al.  Interrater reliability of a modified Ashworth scale of muscle spasticity. , 1987, Physical therapy.

[16]  D. M. Simpson,et al.  Botulinum toxin type A in the treatment of upper extremity spasticity , 1996, Neurology.

[17]  N. Lincoln,et al.  Assessment of motor function in stroke patients. , 1979, Physiotherapy.

[18]  L. A. Koman,et al.  Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. , 1994, Journal of pediatric orthopedics.

[19]  B. Bhakta,et al.  Treatment of chronic limb spasticity with botulinum toxin A. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[20]  L. Provinciali,et al.  Disability Changes After Treatment of Upper Limb Spasticity with Botulinum Toxin , 1996 .

[21]  R. Iman,et al.  Rank Transformations as a Bridge between Parametric and Nonparametric Statistics , 1981 .

[22]  B. Bioulac,et al.  A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. , 1996, Journal of neurology, neurosurgery, and psychiatry.